Global Recombinant Protein Market will Reach Nearly US$ 460 Mn by 2022-end

The global market discussion on recombinant protein industry can be found in the latest study by Fact.MR, which has been freshly added to its massive collection of research database. The report is titled “Recombinant Protein Market Forecast, Trend Analysis & Competition Tracking: Global Review 2017 to 2022”, which works to enlighten the readers about the major factors prompting the growth of the concerned market. Apart from that, the research majorly focuses on recombinant protein market’s competitive outlook by profiling major players functioning across the globe. As the report moves ahead, information regarding the prominent trends as well as opportunities in the key geographical segments have also been elaborated, thus enabling companies to be able to make region-specific strategies for gaining competitive lead. Some of the prime regions emphasized in the study include key regions.

Request for Sample Report- https://www.factmr.com/connectus/sample?flag=S&rep_id=186

A new report published by Fact.MR estimates the global recombinant protein market to witness expansion at a moderate CAGR during the forecast period 2017 to 2022. Revenues from the global recombinant protein market will reach nearly US$ 460 Mn by 2022-end.

Through genetic engineering, and cell engineering, recombinant protein are produced from creature body. The recombinant protein technology now stands at the edge of biotechnology production. Becoming the new standard, this technology is witnessing a gradual shift from bulk production procedure towards post-production techniques, which in turn promises an enhanced delivery and stability. The highly effective recombinant proteins play an integral part in treating specific diseases, such as hemophilia. However, blood coagulation factor is excluded, as it possesses an extremely limited source. A large number of recombinant protein drugs utilized are human proteins. This is mainly to compensate functional proteins in vivo defects, and for increasing the functions of proteins in a body. These factors provide recombinant proteins with substantially higher safety as compared to small molecules, further leading towards higher approval rates.

The clinical trial periods for recombinant proteins are comparatively shorter than small molecule drugs, which further aids in enhancing patient protection, and renders pharmaceutical companies with a relatively longer exclusive sales time. Factors such as these are driving the development, and demand for recombinant proteins. Recombinant proteins target diseases such as cardiovascular diseases, endocrine diseases, viral diseases, and cancer. In addition, the global recombinant protein market has a larger extension space, with few approval drugs available without any alternative products in therapeutic areas. These factors might influence growth of the market over the forecast period. However, factors such as technical barriers, financial barriers have made recombinant protein technology expensive. Moreover, replication of recombinant proteins incurs many challenges, as compared to replication of small molecule chemicals. These factors may impede growth of the market in the near future.

North America to Remain Dominant in the Market

North America will continue to retain its dominance in the global recombinant protein market, with sales projected to reach nearly US$ 150 Mn by 2022-end. Europe is estimated to be the second most lucrative market for recombinant protein throughout the forecast period. The market in Middle East & Africa (MEA) is anticipated to witness a sluggish expansion through 2022.

Recombinant proteins factoring molecular growth will remain the most lucrative product in the market, followed by checkpoint regulators. In addition, sales of growth factors, and cytokines are poised to exhibit similar CAGRs through 2022. However, sales of chemokines are estimated to register the fastest expansion through 2022. Demand for enzymes & inhibitors will continue to be sluggish throughout the forecast period.

Although academic & research institutes are expected to remain the largest end-users of recombinant proteins in terms of revenues, sales in biopharmaceutical companies will register the highest CAGR compared to all the other end-user segments through 2022. Revenues from sales of recombinant proteins in academic & research institutes will account for over one-third market share during 2017 to 2022.

Competition Tracking

Leading players in the global recombinant protein market include Abcam plc, A.M.S. Biotechnology (Europe) Limited, Bio-Rad Laboratories, Inc., BPS Bioscience Inc., PerkinElmer, Inc., Crown Bioscience, Inc., GenScript Corporation, Merck Millipore Limited, Sigma Aldrich, and Thermo Fisher Scientific, Inc.

Browse Full Report with TOC- https://www.factmr.com/report/186/recombinant-protein-market

Table of Content:

1. Global Recombinant Proteins Market - Executive Summary

2. Global Recombinant Proteins Market Overview
2.1. Introduction
2.1.1. Global Recombinant Proteins Market Taxonomy
2.1.2. Global Recombinant Proteins Market Definition
2.2. Global Recombinant Proteins Market Size (US$ Mn) and Forecast, 2012-2022
2.2.1. Global Recombinant Proteins Market Y-o-Y Growth
2.3. Global Recombinant Proteins Market Dynamics
2.4. Regulations
2.5. Supply Chain
2.6. Cost Structure
2.7. Average Pricing Analysis
2.8. List of Distributors
2.9. Key Participants Market Presence (Intensity Map) By Region

3. Global Recombinant Proteins Market Analysis and Forecast By Product Type
3.1. Global Recombinant Proteins Market Size and Forecast By Product Type, 2012-2022
3.1.1. Immune Checkpoint Regulators Recombinant Proteins Market Size and Forecast, 2012-2022
3.1.1.1. Revenue (US$ Mn) Comparison, By Region
3.1.1.2. Market Share Comparison, By Region
3.1.1.3. Y-o-Y growth Comparison, By Region
3.1.2. Chemokines Recombinant Proteins Market Size and Forecast, 2012-2022
3.1.2.1. Revenue (US$ Mn) Comparison, By Region
3.1.2.2. Market Share Comparison, By Region
3.1.2.3. Y-o-Y growth Comparison, By Region

Continued….

Check Discount on This Report- https://www.factmr.com/connectus/sample?flag=D&rep_id=186

About Fact.MR

Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized Healthcare market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us

Fact.MR
Suite 9884
27 Upper Pembroke Street,
Dublin 2, Ireland
Telephone: +353-1-6111-593
Email: sales@factmr.com/
Web: https://www.factmr.com/

This release was published on openPR.